Results 81 to 90 of about 40,708 (270)
Cost-effectiveness analysis of pharmaceutical treatment options in the first-line management of major depressive disorder in Belgium [PDF]
, 2014 The objective of this study was to assess the cost effectiveness of commonly used antidepressants as first-line treatment of major depressive disorder (MDD) in Belgium.
Annemans, Lieven +5 more
core +2 more sources
Is there a role for cannabidiol in obesity, metabolic syndrome and binge eating?
British Journal of Pharmacology, EarlyView.Cannabidiol (CBD) is one of the most abundant phytocannabinoids isolated from the Cannabis sativa plant. CBD is a lipophilic, non‐intoxicating substance that differently from Δ9‐tetrahydrocannabinol (Δ9‐THC) does not present the typical profile of a drug of abuse.
Luca Botticelli +7 more
wiley +1 more source
Novel approaches for drug development against chronic primary pain: A systematic review
British Journal of Pharmacology, EarlyView.Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus +5 more
wiley +1 more source
Gender-related issues in the pharmacology of new anti-obesity drugs [PDF]
, 2019 Four new medicines-liraglutide, lorcaserin, bupropion/naltrexone, and phentermine/topiramate-have been recently added to the pharmacological arsenal for obesity treatment and could represent important tools to manage this epidemic disease.
Barrea, Luigi +6 more
core +1 more source
Circulating levels of proglucagon‐derived peptides are differentially regulated by the glucagon‐like peptide‐1 agonist liraglutide and the centrally acting naltrexone/bupropion and can predict future weight loss and metabolic improvements: A 6‐month long interventional study [PDF]
, 2023 Konstantinos Stefanakis +11 more
openalex +1 more source
Clinical Obesity, Volume 15, Issue 2, April 2025.Summary This study examined the change in weight at 6 months of naltrexone/bupropion (NB), a combination pharmacological therapy for weight management, in real‐world practice in Canada. The study was conducted through an observational, retrospective, single‐arm chart review of adult patients who attended the Wharton Medical Clinic in Ontario, Canada ...
Sean Wharton +4 more
wiley +1 more source
Nicotine-replacement therapy: A proven treatment for smoking cessation [PDF]
, 2010 Smoking is a major cause of cardiovascular diseases, respiratory diseases and cancer. Despite the high prevalence of smokers worldwide, smokers are often neglected and not offered effective assistance with quitting their habits. In order to overcome this
Robson, Noorzurani
core +1 more source
Diabetes, Obesity and Metabolism, EarlyView.Abstract Aims To assess the real‐world effectiveness of semaglutide versus tirzepatide in reducing major adverse cardiovascular events (MACE) among patients with overweight/obesity and established atherosclerotic cardiovascular disease (ASCVD) without diabetes in an insured US population.
Lauren Wilson +6 more
wiley +1 more source
Basic and Clinical Neuroscience, 2014 Introduction: The most common interpretation for the mechanisms of antidepression is the increase of the brain monoamine levels such as dopamine (DA).
Sanaz Amirabadi +5 more
doaj
, 2006 Individual change in behaviour has the potential to decrease the burden of chronic disease due to smoking, diet and low physical activity. Smoking quit rates can be increased by simple advice from a physician or trained counsellor, overall and in ...
Hillsdon, Melvyn +2 more
core +1 more source